Humacyte, Inc. (NASDAQ:HUMA) Short Interest Update

Humacyte, Inc. (NASDAQ:HUMA) was the recipient of a significant growth in short interest in September. As of September 30th, there was short interest totalling 16,030,000 shares, a growth of 14.4% from the September 15th total of 14,010,000 shares. Based on an average daily volume of 3,130,000 shares, the days-to-cover ratio is currently 5.1 days. Currently, 16.4% of the shares of the stock are sold short.

Analyst Ratings Changes

A number of brokerages have recently issued reports on HUMA. BTIG Research raised their price target on shares of Humacyte from $8.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, July 15th. EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. Benchmark restated a “buy” rating and set a $15.00 target price on shares of Humacyte in a report on Thursday, October 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 price target on shares of Humacyte in a research report on Friday, September 20th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $9.80.

Humacyte Stock Up 1.9 %

NASDAQ HUMA traded up $0.11 during trading on Wednesday, reaching $5.81. 3,740,722 shares of the company’s stock were exchanged, compared to its average volume of 2,260,759. The company has a 50 day moving average price of $5.94 and a two-hundred day moving average price of $5.88. The stock has a market cap of $691.88 million, a P/E ratio of -5.89 and a beta of 1.45. Humacyte has a 1 year low of $1.96 and a 1 year high of $9.97. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.41 and a current ratio of 5.41.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). On average, equities research analysts anticipate that Humacyte will post -1.09 EPS for the current fiscal year.

Insider Buying and Selling

In other Humacyte news, Director Brady W. Dougan sold 352,112 shares of Humacyte stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $6.35, for a total transaction of $2,235,911.20. Following the sale, the director now owns 3,677,262 shares of the company’s stock, valued at $23,350,613.70. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director Brady W. Dougan sold 352,112 shares of the company’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $6.35, for a total value of $2,235,911.20. Following the completion of the sale, the director now directly owns 3,677,262 shares in the company, valued at $23,350,613.70. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Brady W. Dougan sold 252,676 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total value of $1,695,455.96. Following the completion of the sale, the director now directly owns 4,306,464 shares of the company’s stock, valued at approximately $28,896,373.44. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,084,153 shares of company stock worth $6,869,996. 23.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Humacyte

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC grew its holdings in shares of Humacyte by 693.0% during the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after purchasing an additional 524,600 shares during the last quarter. Virtu Financial LLC acquired a new position in Humacyte in the 1st quarter valued at about $197,000. Private Advisor Group LLC lifted its position in Humacyte by 232.7% during the 1st quarter. Private Advisor Group LLC now owns 317,624 shares of the company’s stock worth $988,000 after acquiring an additional 222,144 shares during the period. Vanguard Group Inc. grew its stake in shares of Humacyte by 28.7% in the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock valued at $12,501,000 after purchasing an additional 896,415 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Humacyte by 504.3% in the second quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after purchasing an additional 1,334,641 shares during the period. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.